Moderna (Contract Mfg)

Norwood, MA
Find alternatives to Moderna (Contract Mfg) for mRNA →
In-house manufacturer
10 confirmed programs · 4 sponsors · Last scored 2026-10-29
77.9
Signal Score
✓ FDA Inspections (4) ✓ Clinical Trials (10) ✓ SEC Filings (21) ○ Press ✓ EMA GMP (4) ○ MHRA GMP ✓ HC GMP (3)

Quick Facts: Moderna (Contract Mfg)

Signal Score
77.9/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Bonus: 3 consecutive NAI inspections
Headquarters
Norwood, MA
Modalities
mRNA
Active Programs
10 confirmed from ClinicalTrials.gov across 4 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Moderna (Contract Mfg)

mRNA technology leader with internal manufacturing.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Bonus: 3 consecutive NAI inspections
Clean EMA record: 4 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Bonus: 3 consecutive NAI inspections · Clean EMA record: 4 active GMP certificates (no deductions)
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-11-21)
EMA GMP Certificates4 on record
Most Recent HC OutcomeCompliant · 2024-04-16
HC Attribution3 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Bonus: 3 consecutive NAI inspections
Clean EMA record: 4 active GMP certificates (no deductions)
Operations 63.0
10 active programs across 4 sponsors
Modalities: mRNA
8 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
10 active programs across 4 sponsors · Modalities: mRNA · 8 programs in advanced phases (Phase 2/3)
Programs 10
Sponsors4
ModalitiesmRNA
10 active programs across 4 sponsors
Modalities: mRNA
8 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07221474 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab... PHASE2 Recruiting
NCT06946225 ACTengine® IMA203 Combined With mRNA-4203 PHASE1 Recruiting
NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran... PHASE3 Recruiting
NCT06295809 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and... PHASE2/PHASE3 Terminated
NCT06307431 A Study of Adjuvant Intismeran Autogene (V940) and... PHASE2 Active Not Recruiting
NCT06305767 A Clinical Study of Intismeran Autogene (V940) Treatment and... PHASE1/PHASE2 Active Not Recruiting
NCT06077760 A Study of Intismeran Autogene (V940) Plus Pembrolizumab... PHASE3 Recruiting
NCT05533697 Study of mRNA-4359 Administered Alone and in Combination With... PHASE1/PHASE2 Recruiting
NCT04805125 Immunocompromised Swiss Cohorts Based Trial Platform PHASE3 Completed
NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination... PHASE1 Terminated
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
21 SEC filings with industry mentions on record (shown, not scored)
SEC Filings21 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity 53.0
1 manufacturing site: Norwood, MA
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Norwood, MA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Norwood, MA
Modalities: mRNA
Capacity assessment: 53.0/100

Moderna (Contract Mfg) FDA Inspection History

2025-11
2025-03
2024-04
2023-09
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-11-21
Moderna Biotech Spain S.L.
Madrid Facility-linked
Vaccines and Allergenic Products Not posted No Action Indicated (NAI)
2025-03-11
Moderna US Inc.
Cambridge, Massachusetts Facility-linked
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-04-19
ModernaTX, Inc.
Norwood, Massachusetts Company-level
Vaccines and Allergenic Products Not posted No Action Indicated (NAI)
2023-09-21
ModernaTX, Inc.
Norwood, Massachusetts Company-level
Vaccines and Allergenic Products Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Moderna (Contract Mfg) EMA GMP Compliance 4 certificates

2026-06
2024-06
2023-07
2021-11
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
ES/091HVI/26 Moderna Biotech Spain S.L. Spain 2026-06-04 COMPLIANT
ES/096HVI/24 Moderna Biotech Spain S.L. Spain 2024-06-20 COMPLIANT
ES/146HVI/23 Moderna Biotech Spain S.L. Spain 2023-07-26 COMPLIANT
ES/175HVI/21 Moderna Biotech Spain S.L. Spain 2021-11-03 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

biologics · 1 site · own products, not contract-manufacturing evidence

  • Norwood, United States · ModernaTX, Inc. — biologics · valid to Jan 21, 2029

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (100 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
Source: modernatx.wd1.myworkdayjobs.com · Checked Nov 20, 2026

Financial Intelligence

8-K 2026-09-30 0 keyword mentions
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers: (b) and (c) On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026. In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephan"
"Item 7.01 Regulation FD Disclosure: On September 30, 2026, the Company issued a press release announcing the appointment of Mr. Andres as COO. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form"
8-K 2026-09-01 0 keyword mentions
"Item 2.03: Creation of Direct Financial Obligation or an Obligation under an"
"Item 3.02 Unregistered Sales of Equity Securities: The information set forth under Item 1.01 of this Current Report on Form"
10-Q 2026-07-31 6 keyword mentions
"(3) These assets are related to contract manufacturing service agreements."
"Operating expenses Cost of sales Cost of sales for the three months ended June 30, 2026 was $93 million, which included inventory write-downs of $41 million, unutilized manufacturing capacity costs of $23 million, and third-party royalties of $11 million."
"Cost of sales for the six months ended June 30, 2026 was $1.0 billion, which included third-party royalties of $906 million, inventory write-downs of $79 million, and unutilized manufacturing capacity costs of $25 million."
8-K 2026-07-31 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: On July 31, 2026, Moderna, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference."
8-K 2026-07-08 0 keyword mentions
"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers"
"Item 7.01 Regulation FD Disclosure: On July 8, 2026, the Company issued a press release announcing the appointment of Mr. McDonnell to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Report on Form 8-K."
8-K 2026-05-11 0 keyword mentions
"Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year."
10-Q 2026-05-01 3 keyword mentions
"(3) These assets are related to contract manufacturing service agreements."
"Excluding these expenses, cost of sales and cost of sales as a percentage of net product sales and stand-ready manufacturing revenue decreased by 14% and 72 percentage points, respectively, compared to the same period in 2025, primarily due to lower unutilized manufacturing capacity costs, losses on firm purchase commitments and inventory write-downs, partially offset by higher sales volume."
"Interest expense is primarily related to our finance leases related to certain contract manufacturing service agreements and, beginning in November 2025, interest associated with our long-term debt."
8-K 2026-05-01 0 keyword mentions
8-K 2026-03-05 0 keyword mentions
10-K 2026-02-20 38 keyword mentions
"Cell therapy enhancer (mRNA-4203 and Anzu-cel (IMA203)) mRNA-4203 is a cell therapy enhancer that encodes for the target of an ex-vivo cell therapy to enhance the persistence and efficacy of the cell therapy."
"At the commercial stage, we manufacture drug substance and drug product in collaboration with our contract manufacturing organizations (CMOs), both in the United States and internationally."
"In the second quarter of 2023, we acquired a biomanufacturing facility in Marlborough, Massachusetts."
8-K 2026-02-13 0 keyword mentions
8-K 2026-02-11 0 keyword mentions
8-K 2026-01-12 0 keyword mentions
8-K 2026-01-05 0 keyword mentions
10-Q 2025-11-06 9 keyword mentions
"(3) These assets are related to contract manufacturing service agreements."
"Purchase Commitments and Purchase Orders We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services."
"In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors."
10-Q 2025-08-01 9 keyword mentions
"(3) These assets are related to contract manufacturing service agreements."
"Purchase Commitments and Purchase Orders We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services."
"In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors."
10-Q 2025-05-01 7 keyword mentions
"(3) These assets are related to contract manufacturing service agreements."
"Purchase Commitments and Purchase Orders We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services."
"In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors."
10-K 2025-02-21 40 keyword mentions
"At the commercial stage, we manufacture drug substance and drug product in collaboration with our contract manufacturing organizations (CMOs), both in the United States and internationally."
"In the second quarter of 2023, we acquired a newly constructed, 140,000 square feet biomanufacturing facility in Marlborough, Massachusetts."
"From time to time, we also partner with and invest in companies developing other types of therapeutics, such as gene editing and cell-therapy, where we believe we can leverage our core mRNA and LNP capabilities to expand the reach of our technology."
10-Q 2024-11-07 9 keyword mentions
"(3) These assets are real estate assets related to the MTC leases and contract manufacturing service agreements."
"Purchase Commitments and Purchase Orders We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services."
"In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors."
10-Q 2024-08-01 9 keyword mentions
"Purchase Commitments and Purchase Orders We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services."
"In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors."
"As of June 30, 2024, we had cancelable open purchase orders of $ 3.1 billion in total under such agreements for our significant clinical operations and support and contract manufacturing."
10-Q 2024-05-02 7 keyword mentions
"Purchase Commitments and Purchase Orders We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services."
"In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors."
"As of March 31, 2024, we had cancelable open purchase orders of $ 2.6 billion in total under such agreements for our significant clinical operations and support and contract manufacturing."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About Moderna (Contract Mfg)

How many FDA inspections does Moderna (Contract Mfg) have on record?
CDMO Signal tracks 4 FDA inspections for Moderna (Contract Mfg), sourced from the FDA inspection database. See the full inspection history above.
Has Moderna (Contract Mfg) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Moderna (Contract Mfg).
Does Moderna (Contract Mfg) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA GMP certificates for Moderna (Contract Mfg).
How many clinical programs is Moderna (Contract Mfg) linked to?
Moderna (Contract Mfg) is associated with 10 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Moderna (Contract Mfg)'s CDMO Signal Score?
Moderna (Contract Mfg) has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating Moderna (Contract Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Moderna (Contract Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
MassBiologics
Boston, MA
Signal Score: 78.7
AAV, mRNA
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 73.6
mRNA, Gene Therapy, Cell Therapy, Lentiviral
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
Signal Score: 65.5
Cell Therapy, AAV, mRNA
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish

Compare Moderna (Contract Mfg) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Moderna (Contract Mfg)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.